Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,630 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Geriatric 8 screening of frailty in patients with prostate cancer.
Momota M, Hatakeyama S, Soma O, Tanaka T, Hamano I, Fujita N, Okamoto T, Yoneyama T, Yamamoto H, Imai A, Yoshikawa K, Yoneyama T, Hashimoto Y, Ohyama C. Momota M, et al. Among authors: fujita n. Int J Urol. 2020 Aug;27(8):642-648. doi: 10.1111/iju.14256. Epub 2020 Jun 4. Int J Urol. 2020. PMID: 32500621
Effect of frailty and comorbidity on surgical contraindication in patients with localized prostate cancer (FRART-PC Study).
Kodama H, Hatakeyama S, Momota M, Togashi K, Hamaya T, Hamano I, Fujita N, Kojima Y, Okamoto T, Yoneyama T, Yamamoto H, Yoshikawa K, Yoneyama T, Hashimoto Y, Ohyama C. Kodama H, et al. Among authors: fujita n. Urol Oncol. 2021 Mar;39(3):191.e1-191.e8. doi: 10.1016/j.urolonc.2020.06.019. Epub 2020 Jul 17. Urol Oncol. 2021. PMID: 32684512
Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy.
Iwamura H, Hatakeyama S, Narita T, Ozaki Y, Konishi S, Horiguchi H, Kodama H, Kojima Y, Fujita N, Okamoto T, Tobisawa Y, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C. Iwamura H, et al. Among authors: fujita n. Sci Rep. 2022 Jun 11;12(1):9675. doi: 10.1038/s41598-022-13651-x. Sci Rep. 2022. PMID: 35690635 Free PMC article.
Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study.
Fujita N, Hatakeyama S, Tabata R, Okita K, Kido K, Hamano I, Tanaka T, Noro D, Tokui N, Suzuki Y, Yoneyama T, Hashimoto Y, Sato S, Ohyama C. Fujita N, et al. Prostate Int. 2024 Mar;12(1):46-51. doi: 10.1016/j.prnil.2023.12.002. Epub 2023 Dec 19. Prostate Int. 2024. PMID: 38523900 Free PMC article.
2,630 results